Response to the "Australia Usana" incident: Senlue Health only acts as an OEM for two products.

On April 7th, Xianle Health responded to the recent reports on the "Australian Ursini" product on its WeChat public account, stating that the current event is a marketing issue of individual brands and does not involve systemic risks in the production and manufacturing process. The company's quality system, compliance capabilities, and delivery capabilities remain stable. On the same day, in response to whether the "Australian Ursini" brand counterfeiting incident has had an impact on the company's production and operation, Xianle Health-related personnel exclusively responded to a reporter from China Securities Journal, stating that the company has indeed accepted export orders from Guangzhou Yalayuan Health Industry Co., Ltd., with production being handled by its wholly-owned subsidiary Anhui Xianle. However, they only undertook the production of two products for this customer, and not all of their products are produced by the company. Regarding the impact of this incident on the company's production, operation, and order delivery, Xianle Health-related personnel stated that there is no significant impact.